Positive Phase 2 Preliminary Data of SLS009 in R/R AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level Announced
“The remarkable responses achieved in patients with the ASXL1 mutation underscores the transformative potential of SLS009 in addressing the unmet medical needs of AML but also targeting colorectal cancer, and other tumor types with this alteration,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “This is evidenced by strong enthusiasm from the participating investigators reflected in robust enrollment from the clinical sites. These compelling results from the Phase 2a study further reinforce our belief that SLS009 represents a potential breakthrough for relapsed and/or refractory AML patients, and could pave the way for a potential accelerated approval in this defined patient population.”
Share:
More News
“We are encouraged by the progress of our clinical trial and remain focused on our goal to develop innovative therapies that can address glioblastoma and other cancers. Although we are unable to provide detailed information at this stage, we are excited about the continued advancement of this important program,” said
“We are disappointed in the outcome of the RELATIVITY-098 trial and that LAG-3 inhibition in the adjuvant setting did not lead to the same improved efficacy outcomes seen in advanced melanoma,” said Jeffrey Walch, M.D., Ph.D., vice president, Opdualag global program lead, Bristol Myers Squibb. “Patients whose tumors are completely
Ahsan Arozullah, M.D., M.P.H., Senior Vice President, Head of Oncology Development, Astellas said, “The combination of enfortumab vedotin and pembrolizumab was the first approval to offer an alternative to platinum-containing chemotherapy, which had been the standard of care for first-line locally advanced or metastatic urothelial cancer for decades. We are
“U.S. FDA has accepted for review the resubmission of the BLA for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last
